40 results about "Sindbis virus" patented technology

Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain).

The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment, an Eastern equine encephalitis virus cDNA fragment, a Western equine encephalitis virus cDNA fragment or a combination thereof. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.

The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to Sindbis virus vectors which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.

A method for treating malignant tumors with Sindbis viral based vectors in combination with antitumor agents and pharmaceutical formulations for use in such treatment.

Disclosed herein are new defective Sindbis viral vectors made from a novel Helper plasmid, with differences in envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are vectors produced using the plasmid, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.

An object of the present invention is to find a new oncolytic virus and to utilize it for treatment of cancers. The present invention relates to a pharmaceutical composition for treatment of cancers containing Sindbis virus as an active ingredient, a method for treatment of cancers, which comprises administering a therapeutically effective amount of Sindbis virus to a mammal having cancers, a method for identifying cancers, which comprises introducing Sindbis virus into an animal, thereby detecting a Sindbis virus protein or Sindbis virus RNA in vital tissues of the above animal, a method of identifying cancers, which comprises introducing into an animal Sindbis virus having a reporter gene incorporated therein, thereby, detecting the product of said reporter gene in vital tissues of said animal, and a method of identifying cancers, which comprises detecting a increase in antibody titer to the Sindbis virus protein or the product of the reporter gene in the aforementioned animals. It is confirmed that Sindbis virus has cytopathic effects upon various cancer cell lines in vitro, and that reduction in tumor size or disappearance of tumor takes place in vivo. Therefore, Sindbis virus is effective for treatment of cancers. In addition, Sindbis virus shows selective proliferation in a tumor, and is effective for identification or diagnosis for cancers within the living body.

The invention discloses a method for preparing a mouse nerve growth factor (NGF) and a method for preparing a mouse nerve growth factor for injection. The method for preparing the mouse nerve growth factor adopts 100KD and 5KD of ultrafiltration membrane filtration and pasteurization processes on the basis of the conventional process, can effectively filter a macromolecular virus, can further inactivate potential viruses, such as pseudo rabies viruses (PRV), Sindbis viruses, encephalomyo-carditis (EMC) viruses and the like by pasteurization at the same time, does not introduce any pollutant, such as a foreign organic solvent, a detergent and the like, and can keep high purity, high specific activity and high safety of the mouse nerve growth factor.

The invention discloses a method for carrying out virus inactivation on pig fibrinogens through freeze-drying and heating. The method comprises the following steps: carrying out pretreatment on pig plasmas so as to obtain a concentrated pig fibrinogen solution; adding a group protectant into the concentrated solution; adjusting the pH value of the obtained mixture to 7.5-8.5; enabling the obtained mixture to pass a filter with a bore diameter of 0.2mu m; carrying out aseptic filling, freeze-drying and capping seal on the obtained solution by using 2.5mL perfume bottle so as to obtain a freeze-dried pig fibrinogen product; and carrying out heat preservation on the freeze-dried pig fibrinogen product 139-141 hours at a temperature of 63-67 DEG C so as to carry out hot air viral inactivation. The method disclosed by the invention is verified by National Institute for the Control of Pharmaceutical and Biological Products (No.624 [2008] of NICPBP), through adding Sindbis viruses and PPV viruses to carry out verification, the inactivation effect is remarkable. In the method, through using a simple and feasible freeze-drying product virus inactivating method, the requirements for drying and sterilizing aseptic environments are reduced, the risk of animal-based virus infection in pig fiber products is reduced, and the influence (arising from the traditional virus inactivation) on the bioactivities such as proteins and the like of a product is avoided.

The invention discloses a primer probe group and kit for combined detection of Sindbis virus and Getah virus based on a dual fluorescence PCR method. The primer probe group contains specific primers and probes aiming at the Sindbis virus as well as primers and probes aiming at the Getah virus, wherein the specific primers aiming at the Sindbis virus include a forward primer and a reverse primer, the nucleotide sequence of the forward primer aiming at the Sindbis virus is represented by SEQ ID No.1, and the nucleotide sequence of the reverse primer aiming at the Sindbis virus is represented bySEQ ID No.2; and the specific primers aiming at the Getah virus include a forward primer and a reverse primer, the nucleotide sequence of the forward primer aiming at the Getah virus is represented bySEQ ID No.3, and the nucleotide sequence of the reverse primer aiming at the Getah virus is represented by SEQ ID No.4. The primer probe group and the kit utilizing the primer probe group can be usedfor effectively detecting the Sindbis virus and the Getah virus, and the detection sensitivity can reach 1*10<3>copies/ml, so that the detection blanks of the Sindbis virus and the Getah virus in theprior art are effectively overcome, and the primer probe group and the kit have high industrial utilization values.

The present invention describes nucleic acid segments, recombinant alphavirus vectors, and recombinant alphavirus particles that include a Sindbis viral vector. The Sindbis viral vector includes a nucleic acid segment encoding a fusion protein comprising a Sindbis virus nonstructural protein and a protein or peptide of interest, wherein the production of the fusion protein does not affect viral replication or infection. The protein or peptide of interest may be a marker, diagnostic, or therapeutic protein or peptide. Methods of using such recombinant alphavirus particles to kill tumor cells is also described herein.

The present invention is directed to compounds, compositions and methods comprising the aminoglycoside moiety represented by Formula II for treating and preventing the spread of positive sense single-stranded RNA envelope viral infections. One embodiment of the present invention uses geneticin or its analogs, including 2-amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranose, as the antiviral agent. The compounds, compositions and methods of the present invention are applicable to infections resulting from Hepatitis C virus, West Nile virus, Yellow Fever virus, Dengue virus, Bovine Viral Diarrhea virus, Equine Arteritis virus, and/or Sindbis virus.

The invention discloses a method for preparing tetanus human immune globulin by double virus inactivation. The method comprises separating and purifying blood plasma from healthy people containing high-potency tetanus antibody by a low-temperature ethanol protein-separating method, and inactivating virus at the pH value of 4.0 after incubation at 23-25 DEG C for 21 days and treating with DV50 nanometer anti-virus membrane for double virus inactivation. The method of the invention has the beneficial effects that the tetanus human immune globulin prepared by double virus inactivation can greatly reduce disease transmitted by blood products, and the quality of products fully complies with the requirement of Pharmacopoeia of People's Republic of China. Through a test using the pseudorabies virus, Sindbis virus and human immunodeficiency virus (HIV), the virus titer (TCID50) can be decreased by at least 4.00log. The safety and reliability of the products are ensured. The tetanus human immune globulin is particularly suitable for people allergic to tetanus antitoxin (TAT).

The invention discloses a Sindbis virus vector and virus particles thereof, and application of the Sindbis virus vector and virus particles thereof in a neural circuit. The Sindbis virus particles carrying a green fluorescent protein gene are successfully prepared by transfecting cells with the Sindbis virus vector with a nucleotide sequence of SEQ ID NO. 1. The virus particles can infect a plurality of cells in vitro, can replicate and proliferate after infection, and can carry out forward cross-multistage-synapse propagation in a mouse cranial neural circuit; and the virus particles have a wide application value in the aspects of cranial neural circuit marking and tracing, marking of non-human primate nerve cells, establishment of a drug screening platform, research and development of pharmaceutical virus inhibition action mechanisms, viral vaccines and diagnostic reagents, establishment of animal models, analysis of virus replication and pathogenesis mechanisms and the like.

The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment and an Eastern equine encephalitis virus cDNA fragment. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays.

Disclosed herein are methods for identifying cancer cells and monitoring anti-cancer therapy in the body of a mammal by systemically delivering Sindbis viral vectors. The vector can specifically target and identify tumor cells in mice growing subcutaneously, intraperitoneally, intrapancreatically, or in the lungs. These findings demonstrate the remarkable specificity of the Sindbis vector system that is relatively safe and can specifically target tumor cells throughout the body via the bloodstream.

The invention discloses a Sindbis virus overall length plasmid type carrier and its structuring method. The Sindbis virus overall length plasmid type carrier is an expression carrier recombined and structured by a main carrier PsinRep5 and an assistant carrier DH-BB and ESP promoter; firstly, ESP promoter is lead in a main carrier PsinRep5 of the Sindbis virus, and then inserted to DH-BB structure protein gene to obtain the Sindbis virus overall length plasmid type carrier pSinRep 5-DB-ESP; the carrier can directly transfect DNA to the cell, thus the operation of the virus carrier for expressing an exogenous gene is greatly simplified, thus the carrier can be applied to gene expression and also transformation of other viruses; the structuring method has the advantages of being simple in operation, good in safety, able to avoid appearance of recombined wild virus, low in cost, and convenient to popularize and apply.

The invention provides a sindbis virus XJ-160 defective replicon and a construction method and application thereof. The construction method comprises the steps of constructing an XJ-160 virus particle type replicon carrier pVa-XJ, constructing XJ-160 particle type replicons pVaXJ-EGFP and pVaXJ-GLUC containing reporter genes, constructing a XJ-160 defective replicon, utilizing Acl I restriction enzyme to respectively perform single digestion of the VaXJ-EGFP and the pVaXJ-GLUC and constructing defective particles pVaXJ-EGFP delta and pVaXJ-GLUC delta with 1139 base deletions at the positions of non-structural genes. The mechanism of the construction method is that due to the partial absence of non-structural genes regions, a large amount of the reporter genes cannot be expressed normally after cells are introduced into the defective replicon, and non-structural protein expressed by virus can remedy and react on expression of the large amount of the reporter genes caused by the defective replicon when alphavirus infection exists in the cells. The sindbis virus XJ-160 defective replicon can detect multiple types of alphavirus, has not reaction on non-alphavirus and is high in specificity and sensitivity and can detect 1PFU virus. Operation is simple and quick, required instruments are few, sustainability is strong, the virus is not required to be killed in detection, and the sindbis virus XJ-160 defective replicon is suitable for quick identification of the alphavirus.